GlassScriptPhysician profile
Elham M Taheri
NPI 1023547320
$3,333.45
in general payments reported to CMS, 2019-2025
30 companies · $482 in 2025
The $482 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $452 · 2022: $338 · 2023: $985 · 2024: $1,076 · 2025: $482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,543.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,542.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $757.46 | 2021-2025 | |
| Novo Nordisk INC | $479.19 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $322.99 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $232.35 | 2023-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $195.39 | 2022-2025 | Airsupra, Farxiga |
| Otsuka America Pharmaceutical, INC. | $187.66 | 2024-2025 | Rexulti |
| Merz North America, INC. | $178.62 | 2023-2024 | |
| Astellas Pharma US INC | $152.98 | 2024 | Veozah |
| Esperion Therapeutics, INC. | $124.45 | 2023 | Nexletol, Nexlizet |
| Pfizer INC. | $104.25 | 2021-2025 | |
| Corium, LLC | $71.33 | 2022-2023 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $50.73 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $49.77 | 2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Irhythm Technologies, INC. | $46.33 | 2023 | Zio Xt Patch |
| Nevro Corp. | $40.25 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $39.57 | 2023-2025 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $39.31 | 2023-2024 | Injectafer |
| Medtronic, INC. | $27.56 | 2023 | Intellis Adaptivestim |
| Becton, Dickinson and Company | $22.56 | 2025 | Bd Max System, Bd Max Instrument |
| Horizon Therapeutics Plc | $21.89 | 2021 | |
| Mayne Pharma Commercial LLC | $21.75 | 2024 | |
| Ibsa Pharma INC. | $20.35 | 2021 | |
| Axsome Therapeutics, INC. | $20.29 | 2025 | Auvelity |
| Abbott Laboratories | $19.76 | 2025 | Freestyle Libre 3 |
| Amgen INC. | $19.01 | 2025 | Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $18.91 | 2022 | |
| Supernus Pharmaceuticals, INC. | $18.20 | 2022 | |
| Indivior INC. | $17.84 | 2021 | |
| Mylan Specialty L.P. | $16.52 | 2021 | |
| Allergan, INC. | $16.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elham Taheri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.